Endocarditis antithrombotic therapy: Difference between revisions
Jump to navigation
Jump to search
New page: {{SI}} {{CMG}} '''Associate Editors-in-Chief:''' {{CZ}} {{EJ}} ==References== {{reflist|2}} Category:Cardiology Category:Emergency medicine Category:Infectious disease [[... |
No edit summary |
||
| Line 7: | Line 7: | ||
{{EJ}} | {{EJ}} | ||
==Antithrombotic Therapy<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref>== | |||
* [[Anticoagulant]]s can cause or worsen hemorrhage in patients with [[endocarditis]] but may be carefully administered when needed | |||
* The [[prothrombin time]] should be carefully maintained at an INR of 2.0–3.0 | |||
* Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 wk after an acute embolic stroke | |||
* Avoid [[heparin]] administration during active [[endocarditis]] if possible | |||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
Revision as of 19:12, 20 March 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Antithrombotic Therapy[1]
- Anticoagulants can cause or worsen hemorrhage in patients with endocarditis but may be carefully administered when needed
- The prothrombin time should be carefully maintained at an INR of 2.0–3.0
- Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 wk after an acute embolic stroke
- Avoid heparin administration during active endocarditis if possible
References
- ↑ Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.